SCHEMBL335365

SCHEMBL335365

CC(C)(C)N(Cc1ccc(NC(=O)C(O)C(NC(=O)c2ccccc2)c2ccccc2)cc1)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
HPGD P15428 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
USP30 Q70CQ3 1/20 0.41
HDAC1 Q13547 7/20 0.40
HDAC3 O15379 6/20 0.40
HDAC4 P56524 6/20 0.40
HDAC7 Q8WUI4 6/20 0.40
HDAC2 Q92769 6/20 0.40
HDAC10 Q969S8 6/20 0.40
HDAC11 Q96DB2 6/20 0.40
HDAC8 Q9BY41 6/20 0.40
HDAC6 Q9UBN7 6/20 0.40
HDAC9 Q9UKV0 6/20 0.40
HDAC5 Q9UQL6 6/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ATM Q13315 1/20 0.40
CRHBP P24387 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL335366 1.00 LMNA (0.41) LMNAHPGDMEN1KMT2AUSP30
SCHEMBL336126 0.81 LMNA (0.48) LMNAHPGDMEN1KMT2AHDAC1
SCHEMBL4006566 0.79 NAMPT (0.49) MEN1KMT2AHDAC1HDAC10HDAC8
SCHEMBL8214866 0.79 NAMPT (0.49) MEN1KMT2AHDAC1HDAC10HDAC8
SCHEMBL4113391 0.77 KMT2A (0.43) LMNAHPGDMEN1KMT2AALDH1A1
SCHEMBL4113384 0.77 KMT2A (0.43) LMNAHPGDMEN1KMT2AALDH1A1
SCHEMBL335897 0.71 CNR2 (0.50) MEN1KMT2AHDAC1HDAC3HDAC4
SCHEMBL17094907 0.70 POLB (0.58) LMNAMEN1KMT2AHDAC1KDM4E
SCHEMBL15841226 0.69 NPC1 (0.44) LMNAMEN1KMT2AHDAC1HDAC3
SCHEMBL15819934 0.69 NPC1 (0.44) LMNAMEN1KMT2AHDAC1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097758-B2 Isoserine derivatives for use as coagulation factor IXa inhibitors SANOFI-AVENTIS (FR) 2012-01-17 US disclosed
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS SANOFI-AVENTIS (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS TFPI, F2, F9 LMNA 2062/4885HPGD 1026/4885MEN1 2521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.